Antiandrogen-Equipped Histone Deacetylase Inhibitors Selectively Inhibit Androgen Receptor (AR) and AR-Splice Variant (AR-SV) in Castration-Resistant Prostate Cancer (CRPC)

SIMPLE SUMMARY: SBI-46, an antiandrogen-equipped histone deacetylase inhibitor, is the lead compound developed for targeting castration-resistant prostate cancer (CRPC). We determined the anticancer effect of SBI-46 on in vitro and in vivo models of CRPC. In our results, SBI-46 downregulates AR and...

Descripción completa

Detalles Bibliográficos
Autores principales: Chandrasekaran, Balaji, Tapadar, Subhasish, Wu, Bocheng, Saran, Uttara, Tyagi, Ashish, Johnston, Alexis, Gaul, David A., Oyelere, Adegboyega K., Damodaran, Chendil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046692/
https://www.ncbi.nlm.nih.gov/pubmed/36980655
http://dx.doi.org/10.3390/cancers15061769

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046692/
https://www.ncbi.nlm.nih.gov/pubmed/36980655
http://dx.doi.org/10.3390/cancers15061769

Ejemplares similares